Broadening TRAIL's Targets

doi:10.1126/stke.2002.138.tw223

Account Information

Guest Alerts | Access Rights | My Account | Sign In

Site Navigation

Article Views

Abstract
Print View

Article Tools

Help & Feedback

My Science Signaling

Sci. STKE, 25 June 2002
Vol. 2002, Issue 138, p. tw223
[DOI: 10.1126/stke.2002.138.tw223]

EDITORS' CHOICE

APOPTOSIS Broadening TRAIL's Targets

Identifying agents that destroy tumor cells but leave normal cells unharmed is a major goal in developing effective cancer treatments. The cytokine TRAIL, a member of the tumor necrosis family, has shown such potential, as it preferentially induces apoptosis of cancer cells. Now, Kim et al. report a potential mechanism to expand the range of TRAIL cancer targets. Agonists for a nuclear receptor called peroxisome proliferator-activated receptor-gamma (PPAR ${gamma}$ ) sensitized tumor cells that are normally not responsive to TRAIL such that TRAIL did induce apoptosis. Although neither the PPAR ${gamma}$ modulators nor TRAIL alone killed these tumor cells, combined treatment did. Furthermore, the combination did not kill normal cells. The mechanism appears not to involve PPAR ${gamma}$ , because it persisted even in the presence of dominant-negative form of PPAR ${gamma}$ . It seems to be mediated by the formation of a TRAIL receptor-associated signaling complex that activates the cell death program through caspase activation. A cytoplasmic protein called FLIP normally inhibits assembly of this complex, but PPAR ${gamma}$ modulators somehow stimulate the degradation of FLIP through the ubiquitin-proteosome pathway. The cellular target of the PPAR ${gamma}$ modulators that stimulates this proapoptotic effect has yet to be determined.

Y. Kim, N. Suh, M. Sporn, J. C. Reed, An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329 (2002). [Abstract] [Full Text]

Citation: Broadening TRAIL's Targets. Sci. STKE 2002, tw223 (2002).